CN Survey Announcement Box

Article

TALK NERDY TO US TAKE OUR TECH SURVEY FOR A CHANCE AT $500! What are physicians saying, thinking - and doing - when it comes to implementing office technologies? Help us to help you find out by completing our easy survey. We are working with our sister site, PhysiciansPractice.com, to learn all about it -- and we're willing to pay. Just go to the 2012 Tech Survey to complete our easy survey, and enter to win a $500 Visa gift card. It only takes five minutes. The contest will run through February 29th. No purchase is necessary. Void where prohibited. See official rules for full details, available here. Thank you for your participation!

TALK NERDY TO US

TAKE OUR TECH SURVEY FOR A CHANCE AT $500!

What are physicians saying, thinking - and doing - when it comes to implementing office technologies? Help us to help you find out by completing our easy survey.

We are working with our sister site, PhysiciansPractice.com, to learn all about it -- and we're willing to pay. Just go to the 2012 Tech Survey to complete our easy survey, and enter to win a $500 Visa gift card. It only takes five minutes.

The contest will run through February 29th. No purchase is necessary. Void where prohibited. See official rules for full details, available here.

Thank you for your participation!

Related Videos
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Alexander Spira, MD, PhD, FACP, an expert on lung cancer
A panel of 4 experts on lung cancer
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides
Related Content
Biennial screening mammography is recommended for those who are 40 to 74 years old rather than individualizing screening decisions in this age group.

USPSTF Recommends Breast Cancer Screening Starting at Age 40

May 1st 2024
Article

Biennial screening mammography is recommended for those who are 40 to 74 years old rather than individualizing screening decisions in this age group.

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

Applying Novel Radiotherapy Technology for Brain Tumors and Other Cancers

April 29th 2024
Podcast

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

Safety findings highlight no severe adverse effects or dose-limiting toxicities with the rintatolimod combination in late-stage pancreatic cancer.

Rintatolimod/Durvalumab Dose Appears Tolerable in Pancreatic Cancer

April 30th 2024
Article

Safety findings highlight no severe adverse effects or dose-limiting toxicities with the rintatolimod combination in late-stage pancreatic cancer.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Amivantamab/chemotherapy has been recommended for approval by the CHMP in advanced non–small cell lung cancer with EGFR exon 20 insertion mutations.

CHMP Promotes Positive Opinion of Amivantamab in EGFR Exon 20+ NSCLC

April 29th 2024
Article

Amivantamab/chemotherapy has been recommended for approval by the CHMP in advanced non–small cell lung cancer with EGFR exon 20 insertion mutations.

FDA Approves Tisotumab Vedotin for Recurrent/Metastatic Cervical Cancer

FDA Approves Tisotumab Vedotin for Recurrent/Metastatic Cervical Cancer

April 29th 2024
Article

Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.